Nguyen, a 34-year-old motorcycle driver in Hanoi, spent months coughing, losing weight, and missing work. When he finally went to the clinic, tests showed he had tuberculosis. But not just any kind — one that didn’t respond to standard drugs. By the time doctors found the right treatment, his infection had spread.
He’s not alone. Vietnam ranks among the top 20 countries with the most cases of drug-resistant TB. Nearly 10,000 people there face this form of TB each year. Standard treatments often fail. Delays in diagnosis mean patients suffer longer and can spread the disease before getting help.
This doesn’t mean this treatment is available yet.
Most clinics test for resistance to just one or two drugs. The assumption has long been: if TB resists rifampicin, the cornerstone drug, doctors start a second-line regimen. But what if that’s not enough?
But here’s the twist: new research shows most rifampicin-resistant TB in Vietnam doesn’t stop there. It’s already resistant to other key antibiotics — even before treatment begins.
Think of TB bacteria like locks and keys. Antibiotics are keys that fit specific bacterial locks. When a mutation occurs, the lock changes shape. The key no longer works. Rifampicin is one key. But in Vietnam, many of these bacterial “locks” have changed in multiple places at once.
That means the bacteria are not just resistant to rifampicin — they’re often resistant to isoniazid, levofloxacin, and even newer drugs like linezolid and bedaquiline. It’s like a lock that no longer fits any of the keys in your ring.
Scientists studied 252 TB samples from patients across 10 provinces. These weren’t just from big cities — they included rural areas often left out of research. Each sample was tested using whole genome sequencing, a method that reads the bacteria’s DNA like a book.
What they found stunned experts. Of the 244 confirmed rifampicin-resistant cases, 96% were also resistant to at least one other major drug. Even more surprising: one strain, called lineage 2.2.1, dominated across regions. It’s spreading — and it’s tough to treat.
One strain to rule them all
This strain isn’t new, but its reach is. It’s especially common in Hanoi and Ho Chi Minh City, but now shows up in provinces far from urban centers. That suggests it’s not just local spread — people may be carrying it from city to countryside, or vice versa.
The good news? Modern tests like Xpert MTB/RIF caught rifampicin resistance accurately in 97% of cases. And when researchers checked resistance predictions from DNA against lab tests, the match was strong — over 90% for most drugs.
For newer drugs, the news was even better. Linezolid and pretomanid resistance predictions were 100% accurate in tested samples. Bedaquiline was close behind at 93%. That means genetic testing could safely guide treatment without waiting weeks for lab cultures.
But there's a catch.
While DNA testing is fast and accurate, it’s still not available in many clinics across Vietnam. Most patients still rely on older, slower methods. That delay can cost lives. And even when tests are done, access to second-line drugs isn’t guaranteed.
Experts say this data changes the game. If most resistant TB is multi-resistant from the start, doctors need broader testing upfront — not step-by-step guesses. Waiting to see what fails wastes precious time.
For patients, this means faster, smarter treatment could be possible — if the system adapts. It’s not about new drugs alone. It’s about using the right ones sooner.
Still, there are limits. This study looked at lab-cultured samples, which can be harder to get from very sick patients. And while genome sequencing is powerful, it’s not perfect. Rare mutations might still slip through.
The road ahead starts now. Vietnam’s health leaders are using this data to push for wider access to genetic testing. Clinical labs are being trained. The goal: make advanced testing routine, not rare.
New trials are already in motion to test whether starting broad treatment based on DNA results leads to better outcomes. If so, this approach could spread to other high-burden countries — from Indonesia to South Africa.
For millions at risk, the message is clear: knowing more, faster, could save lives. And in the fight against TB, time is everything.
